journal article·2019-12-01Open access

The investigation of 2D monolayers as potential chelation agents in Alzheimer’s disease

N. Pavuluru, X. Luo

AIP Advances· Volume 9· Issue 12

Abstract

In this study, we conducted density functional theory calculations comparing the binding energy of the copper-amyloid-β complex to the binding energies of potential chelation materials. We used the first-coordination sphere of the truncated high-pH amyloid-β protein subject to computational limits. Binding energy and charge transfer calculations were evaluated for copper’s interaction with potential chelators: monolayer boron nitride, monolayer molybdenum disulfide, and monolayer silicene. Silicene produced the highest binding energies to copper, and the evidence of charge transfer between copper and the monolayer proves that a strong ionic bond is present. Although our three monolayers did not directly present chelation potential, the absolute differences between the binding energies of the silicene binding sites and the amyloid-β binding sites were minimal, proving that further research in silicene chelators may be useful for therapy in Alzheimer’s disease.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Graphene research and applications · Alzheimer's disease research and treatments · Synthesis and Properties of Aromatic Compounds

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

National Graphene Research and Development Center , Springfield, Virginia 22151, USA

References (51)

Show source-provided references
1. Dysfunction of NMDA receptors in Alzheimer’s disease10.1007/s10072-016-2546-5 ↗
2. Synapse loss in frontal cortex biopsies in Alzheimer’s disease: Correlation with cognitive severity10.1002/ana.410270502 ↗
3. Family cohesion: A study on caregiving daughters of parents with Alzheimer’s disease10.5964/ijpr.v10isupp1.244 ↗
4. Alzheimer’s neurofibrillary pathology and the spectrum of cognitive function: Findings from the nun study10.1002/ana.10161 ↗
5. Tau protein hyperphosphorylation and aggregation in Alzheimer’s disease and other tauopathies, and possible neuroprotective strategies10.3390/biom6010006 ↗
6. In vivo localization of human acetylcholinesterase-derived species in a β-sheet conformation at the core of senile plaques in Alzheimer’s disease10.1074/jbc.ra118.006230 ↗
7. Familial Alzheimer’s disease mutations within the amyloid precursor protein alter the aggregation and conformation of the amyloid-β peptide10.1074/jbc.m116.755264 ↗
8. Inhibition of Alzheimer β-fibrillogenesis by melatonin10.1074/jbc.273.13.7185 ↗
9. A specific amyloid-β protein assembly in the brain impairs memory10.1038/nature04533 ↗
10. Amyloid-beta: A crucial factor in Alzheimer’s disease10.1159/000369101 ↗
11. Metal ions affect the formation and stability of amyloid β aggregates at multiple length scales10.1039/c7cp05072k ↗
12. Biological metals and metal-targeting compounds in major neurodegenerative diseases10.1039/c4cs00138a ↗
13. Metal ions and amyloid fiber formation in neurodegenerative diseases. copper, zinc and iron in Alzheimer’s, Parkinson’s and prion diseases10.1016/j.ccr.2012.05.003 ↗
14. Role of metal ions in the self-assembly of the Alzheimer’s amyloid-β peptide10.1021/ic4003059 ↗
15. Metals and Alzheimer’s disease: How far have we come in the clinic?10.3233/jad-170662 ↗
16. Interactions of Zn(ii) and Cu(ii) ions with Alzheimer’s amyloid-beta peptide. Metal ion binding, contribution to fibrillization and toxicity10.1039/c0mt00073f ↗
17. Elucidating the 3D structures of Al(iii)–Aβ complexes: A template free strategy based on the pre-organization hypothesis10.1039/c7sc01296a ↗
18. Metal-binding to amyloid-β peptide: Coordination, aggregation, and reactive oxygen species production10.1016/B978-0-12-804562-6.00014-2 ↗
19. Transition metal ion interactions with disordered amyloid-β peptides in the pathogenesis of Alzheimer’s disease: Insights from computational chemistry studies10.1021/acs.jcim.8b00983 ↗
20. Identifying the minimal copper- and zinc-binding site sequence in amyloid-β peptides10.1074/jbc.m707109200 ↗
21. Alzheimer’s disease amyloid-β binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits10.1074/jbc.m100175200 ↗
22. Benchmarking of copper(ii) LFMM parameters for studying amyloid-β peptides10.1080/07391102.2017.1313780 ↗
23. The structure of the amyloid-β peptide high-affinity copper ii binding site in Alzheimer disease10.1529/biophysj.108.134429 ↗
24. Cu2+ affects amyloid-β (1–42) aggregation by increasing peptide-peptide binding forces10.1371/journal.pone.0059005 ↗
25. Copper binding to the amyloid-β (Aβ) peptide associated with Alzheimer’s disease folding, coordination geometry, pH dependence, stoichiometry, and affinity of Aβ-(1–28): Insights from a range of complementary spectroscopic techniques10.1074/jbc.m313572200 ↗
26. On the involvement of copper binding to the N-terminus of the amyloid beta peptide of Alzheimer’s disease: A computational study on model systems10.4061/2011/539762 ↗
27. Cu and Zn interactions with Aβ peptides: Consequence of coordination on aggregation and formation of neurotoxic soluble Aβ oligomers10.1039/c8mt00203g ↗
28. Ab initio design of chelating ligands relevant to Alzheimer’s disease: Influence of metalloaromaticity10.1021/jp203465h ↗
29. The role of metals in amyloid aggregation—Experiments and ab initio simulations10.1002/qua.21724 ↗
30. Coordination abilities of the 1–16 and 1–28 fragments of β-amyloid peptide towards copper(ii) ions: A combined potentiometric and spectroscopic study10.1016/s0162-0134(03)00128-4 ↗
31. Role of aspartate-1 in Cu(ii) binding to the amyloid-β peptide of Alzheimer’s disease10.1021/ja068952d ↗
32. The chemistry of Alzheimer’s disease10.1039/b807980n ↗
33. Biometals and their therapeutic implications in Alzheimer’s disease10.1007/s13311-014-0312-z ↗
34. Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer’s disease: A phase IIa, double-blind, randomised, placebo-controlled trial10.1016/s1474-4422(08)70167-4 ↗
35. Boron nitride nanotubes: Production, properties, biological interactions and potential applications as therapeutic agents in brain diseases10.2174/157341311794480345 ↗
36. Molybdenum disulfide nanoparticles as multifunctional inhibitors against Alzheimer’s disease10.1021/acsami.7b03816 ↗
37. Silicon-rich mineral water as a non-invasive test of the ‘aluminum hypothesis’ in Alzheimer’s disease10.3233/JAD-2012-121231 ↗
38. Insights into the oxygen-based ligand of the low pH component of the Cu2+-amyloid-β complex10.1021/jp5047529 ↗
39. On the metal ion (Zn2+, Cu2+) coordination with beta-amyloid peptide: DFT computational study10.1007/s12539-010-0086-x ↗
40. Pleomorphic copper coordination by Alzheimer’s disease amyloid-β peptide10.1021/ja808073b ↗
41. Theoretical and NMR conformational studies of β-proline oligopeptides with alternating chirality of pyrrolidine units10.3389/fchem.2018.00091 ↗
42. Projector augmented-wave method10.1103/physrevb.50.17953 ↗
43. Generalized gradient approximation made simple10.1103/physrevlett.77.3865 ↗
44. ABINIT: First-principles approach of materials and nanosystem properties10.1016/j.cpc.2009.07.007 ↗
45. A brief introduction to the ABINIT software package10.1524/zkri.220.5.558.65066 ↗
46. 3D structures and redox potentials of Cu2+–Aβ (1–16) complexes at different pH: A computational study10.1021/jp5019718 ↗
47. Origin of differences in the excess volume of copper and nickel grain boundaries10.1016/j.actamat.2016.02.040 ↗
48. Graphene, hexagonal boron nitride, and their heterostructures: Properties and applications10.1039/c7ra00260b ↗
49. Phonons in single-layer and few-layer MoS2 and WS210.1103/physrevb.84.155413 ↗
50. Silicene on metal and metallized surfaces: Ab initio studies10.1088/1367-2630/16/7/075004 ↗
51. Stability, dynamics, and lubrication of MoS2 platelets and nanotubes10.1021/la300871q ↗